Skip to main content
Vivo Bio tech Ltd. logo

Vivo Bio tech Ltd. — Investor Relations & Filings

Ticker · 511509 ISIN · INE380K01017 LEI · 98450079E4M2CR80D882 BSE.NS Professional, scientific and technical activities
Open in API
Filings indexed 440 across all filing types
Latest filing 2025-01-09 Regulatory Filings
Country IN India
Listing BSE.NS 511509

About Vivo Bio tech Ltd.

http://www.vivobio.com/

Vivo Bio Tech Ltd. is a preclinical Contract Research Organization (CRO) providing comprehensive drug discovery and development services. The company specializes in conducting in vivo preclinical studies, including toxicology, pharmacology, and pharmacokinetic evaluations. It operates advanced facilities for the breeding and distribution of Specific Pathogen Free (SPF) laboratory animal models, maintained through strategic partnerships with global leaders like Taconic Biosciences. Vivo Bio Tech offers regulatory-compliant services such as safety assessment, efficacy testing, and specialized research models to support pharmaceutical and biotechnology sectors. Its operations are characterized by adherence to Good Laboratory Practice (GLP) standards and AAALAC accreditation, ensuring high-quality data for global regulatory submissions.

Recent filings

Filing Released Lang Actions
Please find enclosed outcome of the Board Meeting
Regulatory Filings
2025-01-09 English
Outcome of the Board Meeting
Regulatory Filings
2025-01-09 English
Disclosure of voting results and scrutinizer''s report
Regulatory Filings
2025-01-06 English
VIVO BIO TECH LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/01/2025 ,inter alia, to consider and approve Update on board meeting
Regulatory Filings Classification · 95% confidence The document is a prior intimation of a Board Meeting scheduled for January 9, 2025, referencing Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It informs about the agenda items related to raising funds through equity shares or other instruments and the convening of an Extraordinary General Meeting or Postal Ballot for shareholder approval. The document is a formal notice to the stock exchange and stakeholders about the upcoming Board meeting and its agenda, not the meeting minutes or detailed report itself. The document length is short (3138 characters) and serves as an announcement rather than a detailed report or financial statement. Therefore, it fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2025-01-04 English
VIVO BIO TECH LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/01/2025 ,inter alia, to consider and approve the Un-Audited Standalone & ....
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the stock exchange (BSE Limited) informing about the date of the upcoming Board Meeting scheduled for January 9, 2024. It references Regulation 29(1)(a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of Board Meeting dates. The letter states that the Board will consider and approve the un-audited financial results for the third quarter and nine months ended December 31, 2024, but does not contain the financial results themselves. The document is short (1660 characters) and serves as an intimation or announcement of the Board Meeting date, not the actual financial report or results. Therefore, it is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement and does not fit other specific categories like Interim Report or Earnings Release. It is not a Management Information or Board/Management Information announcement about changes in directors, but a notice of meeting date and agenda.
2025-01-02 English
Closure of Trading Window
Regulatory Filings Classification · 95% confidence The document is a short notice informing the stock exchange about the closure of the trading window in compliance with SEBI regulations ahead of the announcement of the company's un-audited financial results for the third quarter and nine months ended December 31, 2024. It does not contain any financial data or detailed report but is an announcement related to insider trading restrictions. The document length is only 1507 characters, indicating it is a brief regulatory announcement rather than a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS).
2024-12-30 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.